Three oncology perspectives have analyzed a cancer case: Tumor Board: Guidelines: The diagnosis of 'metastatic...

Question asked:

Three oncology perspectives have analyzed a cancer case: Tumor Board: Guidelines: The diagnosis of 'metastatic castration-resistant presumed' is INCORRECT and incomplete based on current evidence. This patient has hormone-sensitive oligometastatic prostate cancer (pT3b/pT4a pN1, Gleason 4+5=9) with undetectable ctDNA (Signatera 0.0 MTM/mL as of November 2025) and PSA 0.4-0.56 ng/mL while on adaptive bipolar androgen therapy (aBAT). The patient is NOT castration-resistant—he is actively responding to hormonal manipulation via aBAT, which by definition means hormone-sensitive disease. Recommendation: CORRECT DIAGNOSIS: Hormone-sensitive oligometastatic prostate cancer, post-prostatectomy, pT3b/pT4a pN1, Gleason 4+5=9, with biochemical recurrence and nodal oligometastases, currently controlled on adaptive bipolar androgen therapy (aBAT). Confirm current hormone-sensitive status with testosterone level during low-T phase of aBAT cycle (<50 ng/dL qualifies as 'castrate' even if therapeutically induced). Consider PSMA-directed therapy (SBRT) to remaining oligometastatic nodes given excellent systemic control and HRD genotype favoring consolidative local therapy per NCCN Category 2A recommendation for oligometastatic hormone-sensitive disease. Tumor Board: Cutting Edge: The diagnosis of 'metastatic castration-resistant presumed' is INCORRECT and incomplete based on current evidence. This patient has hormone-SENSITIVE oligometastatic prostate cancer (pT3b/pT4a pN1, Gleason 4+5=9) currently in biochemical/radiographic remission on adaptive BAT therapy, with undetectable ctDNA (Signatera 0.0 MTM/mL as of Nov 2025) and minimal PSMA-avid disease (stable 4mm lymph node, SUVmax 2.4). The patient has never progressed on continuous ADT to meet PCWG3 criteria for castration resistance. Recommendation: Correct diagnosis to 'High-risk hormone-SENSITIVE oligometastatic prostate adenocarcinoma (pT3b-4a pN1, Gleason 9, HRD+) in biochemical/radiographic remission on experimental aBAT therapy.' Confirm current testosterone levels, repeat Signatera ctDNA in 8-12 weeks, and obtain PSMA PET every 6 months to monitor oligoprogression. If future progression occurs ON castrate testosterone levels with rising PSA, THEN reclassify as mCRPC and pursue genomically-matched trials (PARPi combinations, platinum-based regimens, or integrin-targeted immunotherapy per Dr. [removed] paradigm given likely basal-enriched phenotype from TP53/PTEN pathway alterations). Tumor Board: Whole Person: The diagnosis of 'metastatic castration-resistant presumed' prostate cancer is INCOMPLETE and likely INACCURATE based on current evidence. Russell has hormone-SENSITIVE prostate cancer (HSPC) with oligometastatic disease currently showing excellent treatment response (undetectable ctDNA on Signatera 11/2025, PSA 0.4-0.56 ng/mL, testosterone 28 ng/dL indicating castrate levels). He has NOT progressed to castration-resistant disease, as his PSA remains suppressed while on androgen deprivation. Recommendation: The accurate diagnosis should be: 'High-risk hormone-sensitive prostate cancer (HSPC), status post radical prostatectomy 2018, with oligometastatic recurrence (pelvic/retroperitoneal lymph nodes), currently in excellent biochemical and molecular response to adaptive bipolar androgen therapy (aBAT) with undetectable ctDNA.' Confirm current treatment phase (high-T vs low-T phase of aBAT cycle), verify PSA trend over last 6 months, and establish clear criteria for defining progression to CRPC (PSA rise >2.0 ng/mL on consecutive tests while testosterone <50 ng/dL, or radiographic progression per PCWG3 criteria). Synthesize these perspectives. Respond in this exact JSON format: { "synthesis": "A 2-3 sentence synthesis of the key takeaways for the patient", "consensus": ["Point where all three agree", "Another point of agreement"], "divergence": ["Point where they disagree", "Another area of disagreement"] } Focus on actionable insights for the patient's next doctor conversation.